Anzeige
Mehr »
Dienstag, 09.06.2026 - Börsentäglich über 12.000 News
Pentagon in Alarmbereitschaft? Dieser Rohstoff könnte jetzt Gold in den Schatten stellen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
106 Leser
Artikel bewerten:
(0)

Okmetic Oyj: INTERIM REPORT 1 JANUARY - 31 MARCH 2012: BOTTOM PASSED IN THE SEMICONDUCTOR CYCLE, ORDERS INCREASING AGAIN

OKMETIC OYJ  STOCK EXCHANGE RELEASE   27 APRIL 2012  AT 8.00 A.M.

INTERIM REPORT 1 JANUARY - 31 MARCH 2012: BOTTOM PASSED IN THE SEMICONDUCTOR CYCLE, ORDERS INCREASING AGAIN

Unless otherwise stated, figures in parenthesis refer to the corresponding period in the previous year.

JANUARY-MARCH IN BRIEF:

  • Net sales amounted to 18.9 (22.1) million euro, down 14.3%.
  • Operating profit was 1.5 (2.8) million euro corresponding to 8.1% of net sales.
  • Profit for the period was 0.7 (2.7) million euro.
  • Basic earnings per share was 0.04 (0.16) euro.
  • Net cash flow from operations amounted to -1.0 (-1.3) million euro.

PROJECTIONS FOR THE NEAR FUTURE

The customer industries are estimated to grow moderately in Okmetic's main product groups in 2012. The levelling of semiconductor industry's inventories, which started in mid-2011, seems to have ended in the end of the period under review, as anticipated. The orders of semiconductor wafers began to increase in March. This indicates that the downward trend of around three quarters has ended.

The development of sensor wafer demand is estimated to be somewhat more stable in 2012 than the demand for semiconductor wafers. The growth of sensor wafer demand seems to focus on the second half of the year, while the beginning of the year is still a time of lower demand.

Technology sales will focus on solar crystal sales, and be fairly even until the shipment contracts that are valid until the third quarter will be terminating. The solar cell industry's strongly lowered price level is likely to accelerate the consolidation in the industry. This development has no direct effects on Okmetic's technology business.

The company retains the existing guidance, according to which the net sales and operating profit for 2012 are estimated to exceed the level of 2011, although they remained under the level of the comparison period in the first quarter, as anticipated.

PRESIDENT KAI SEIKKU:

"The semiconductor market which took a downward turn in summer 2011 hit the rock bottom in January-February. The long-awaited turn for the better was evident in March, after which the order backlog has started to grow. As predicted, Okmetic's net sales and operating profit in the first quarter remained under the strong level of the comparison period. Thanks to the sales efforts the company's market share rose to a record level in the first quarter in the product groups important to the company, which partly softened the impact of the steep market drop on the company's operation.

The operating profit of the first quarter was lowered significantly due to a disturbance that took place in the production chain of a gas in the USA. The gas is used in the manufacture of epi-coated wafers. In practice, Okmetic's Allen production plant had to be idled for almost a month. The shipments of epi wafers during the shutdown were only a fraction of the order backlog, and the first quarter in the US-based subsidiary was in this respect unprofitable.

The delivery disturbance that burdened the entire industry in the US was caused by a fault in the process of the only gas supplier on the market. The fault has since been located and fixed. The company believes it can deliver majority of the lost orders during the rest of the year.

In the first quarter, the operating profit was also weakened by the less advantageous product mix compared to the previous quarter and to the corresponding quarter last year, some non-recurring expense items related to foreign subsidiaries, and the changes in the fair value of electricity derivatives as the price of electricity declined further. The capacity utilisation rate was deliberately maintained partly with products of lower margin.

Despite the several challenges, the operating profit (8.1%) in the first quarter nearly reached the minimum level of 10 percent which is the company's long-term objective. The factors behind the success are the business volume that has increased in recent years and the supply chain that is more flexible than before and continuously under development.

The clear decline in the profit for the period in relation to the comparison period was caused not only by lower operating profit but also by a difference of nearly one million euro in income tax entered as expenses. Along with the good profitability development in recent years, Okmetic managed to deduct the earlier confirmed losses from its result by the end of summer 2011. Similar to last year, the net cash flow of the period under review was weighed down by advance payments and working capital items. The cash flow is expected to improve in the end of the year, the same as last year.

The demand for semiconductor wafers has clearly picked up as of March, which predicts strong development starting from the second quarter. The demand for sensor wafers, on the contrary, will probably reach full speed a little later, that is, during the second half of the year. The demand for sensor wafers has been restrained by high inventory levels and the increasing focus of sensors on consumer electronics, exposed to economic fluctuations. In the period under review, technology sales consisted largely of solar crystal sales."

KEY FIGURES

1,000 euro 1.1.-
31.3.12
1.1.-
31.3.11
1.1.-
31.12.11
1.1.-
31.12.10
Net sales 18,902 22,055 83,186 80,907
Operating
profit
before
depreciation
(EBITDA)




3,052




4,425




18,069




17,102
Operating
profit

1,535

2,828

11,817

10,421
 % of net sales 8.1 12.8 14.2 12.9
Profit for
the period

712

2,724

10,235

9,952
Basic earnings
per share,
euro


0.04


0.16


0.61


0.60
Net cash flow
from operating
activities


-996


-1,337


11,691


16,594
Net interest-
bearing
liabilities


-6,071


-12,379


-10,257


-18,047
Equity ratio, % 79.2 78.9 78.9 76.6
Average number
of personnel
during the period


351


347


363


345

MARKETS

Customer industries sensor, semiconductor, and solar cell industries

Sensor industry

In 2012, the sale value of sensor industry is estimated to grow 11-15 percent compared to the sale value of 2011 (8.6-10.2 billion US dollars). One of the fastest growing sectors is MEMS products for consumer applications such as microphones and gyroscopes. In the next few years picoprojectors are estimated to be a significant growth area in consumer applications. (IHS iSuppli, IC Insights, Yole) Nowadays, silicon-on-insulator (SOI) technology is widely used in the manufacture of these next generation products, and the share of SOI technology is estimated to continue its growth. Okmetic is amongst the pioneering suppliers who provide products and services based on SOI technology to the sensor industry.

Semiconductor industry

The US dollar based sales of the semiconductor industry have started to recover during the first quarter of the year. The estimates for the sale development in 2012 have improved and they settle now at a level of 3-7 percent of annual growth. (IHS iSuppli, Gartner, IC Insights, VLSI Research)

The growth in demand that started in the first quarter of 2012 is expected to accelerate in the second half of the year (IDC). The demand for semiconductors is boosted by both strongly increasing applications, such as tablet computers, and the uplift of developing markets (Gartner).

In the long run, the growth rate of semiconductor demand is estimated to remain at a yearly level of 5-9 percent (IDC, IC Insights). The growth rate of discrete and power semiconductors is estimated to slightly exceed the semiconductor market average (IC Insights, IHS iSuppli, Yole).  

Solar cell industry

The almost 10-year-long very strong 40-50 percent annual growth of new solar energy based (Photovoltaic) power plants is moderating. On average, annual growth of 20-30 percent is estimated for the near future. (IHS iSuppli) The use of solar energy for electricity production is expanding to more and more countries as the costs go down. Already over 20 countries are estimated to build more than 100MW of capacity during 2012. (IMS Research)  

In the short run, the changes in feed-in tariffs in Germany and Italy create uncertainty in the market. Significant overproduction and structural change throughout the industry's supply chain are predicted to continue during 2012.

Silicon wafer market

According to the statistics published in February 2012 by SMG, the group of silicon wafer suppliers in SEMI, the surface area of wafer shipments in the whole silicon wafer industry in 2011 decreased by three percent compared to 2010 area shipments. The transfer of the market to bigger wafer sizes along with the technological development was stronger than average. Compared to the previous year, a growth of three percent is estimated for 2012.

Okmetic's central customer areas in the silicon wafer market

In line with its strategy, Okmetic seeks for special areas of the entire silicon wafer market that have greater growth rates than the market average and in which the company has special expertise. Okmetic supplies primarily 150mm and 200mm wafers. The sensor/MEMS industry is Okmetic's central growth area. The MEMS market grows as portable consumer products, automotive electronics, and industrial process control increase.

In the semiconductor market, Okmetic's growth areas include discrete and power semiconductors. The growth areas of these markets are i.a. components used in the production of renewable energy, increasing automotive electronics, portable consumer products, as well as different solutions related to power supply and efficiency improvement.

SALES

In January-March, Okmetic's net sales amounted to 18.9 (22.1) million euro. There was a decrease of 14.3 percent (growth 33.5%) for the comparison period mainly due to the prevailing market trend. Okmetic's market share grew in the product groups which are important to the company, and sales improved clearly towards the end of the first quarter because of the strengthened economic situation.

Sales per customer area

1.1.-
31.3.12
1.1.-
31.3.11
1.1.-
31.12.11
1.1.-
31.12.10
Sensors 46% 45% 46% 43%
Semiconductors 34% 33% 35% 42%
Technology 20% 22% 19% 15%

In January-March, the value of sensor wafer shipments was 14.0 percent lower than in the corresponding period last year. Sensor wafer sales were weighed down by the customers' bloated inventory levels in the beginning of the year. The demand for sensor wafers is expected to pick up in the second half of the year.

The downward trend in the semiconductor industry saw a clear change at the end of the first quarter which contributed positively to the semiconductor wafer sales. Due to the low demand in January-February, the shipment value of the first quarter was 10.3 percent lower than in the corresponding period last year.

In January-March, technology sales consisted mainly of solar crystal sales.

Sales per market area

1.1.-
31.3.12
1.1.-
31.3.11
1.1.-
31.12.11
1.1.-
31.12.10
North America 36% 37% 37% 43%
Europe   26% 31% 30% 25%
Asia  38% 32% 33% 32%

In the first quarter, the sales were strongest in Asia and North America. The relative proportion of Asia of the net sales grew during the period under review.

PROFITABILITY

January-March

In January-March, Okmetic's operating profit was 1.5 (2.8) million euro. The operating profit accounted for 8.1 (12.8) percent of net sales. Profit for the period amounted to 0.7 (2.7) million euro. Basic earnings per share was 0.04 (0.16) euro. Diluted earnings per share was 0.04 (0.16).

FINANCING

The company's financial situation is good. In January-March, net cash flow from operations amounted to -1.0 (-1.3) million euro. The cash flow from operations was weakened by 3.9 (6.0) million euro due to changes in working capital available to business operations.

On 31 March 2012, the company's liabilities amounted to 1.0 (1.0) million euro.

At the end of the period, cash and cash equivalents amounted to 7.2 (10.4) million euro. On 31 March 2012, the company's cash and cash equivalents exceeded the interest-bearing liabilities by 6.2 million euro (on 31 March 2011, cash and cash equivalents were 12.4 million euro higher than interest-bearing liabilities). The group has ensured the sufficiency of cash funds by increasing the committed credit facility of 3.0 million euro to 6.0 million euro. The credit facility was undrawn on 31 March 2012.

Return on equity amounted to 4.6 (18.3) percent. The company's equity ratio was 79.2 (78.9) percent. Equity per share was 3.69 (3.63) euro.

INVESTMENTS

In January-March, Okmetic's capital expenditure amounted to 2.6 (4.8) million euro.

The investments concerned mainly the board's decision in April 2011 to increase SOI wafer production capacity by extending the Vantaa plant. The around 30 million euro investment programme, to be implemented in 2011-2013, includes the plant extension and different kinds of production equipment. Building of the plant extension started in August 2011.

PRODUCT DEVELOPMENT

In January-March, the company expensed 0.5 (0.6) million euro in product development projects. Product development costs accounted for 2.8 (2.7) percent of net sales. The product development costs have not been capitalised. Product development has been allocated to SOI wafers and high and low resistivity wafers.

PERSONNEL

On average, Okmetic employed 351 (347) people in January-March. At the end of the period, 311 of the company's employees worked in Finland, 36 in the US, four in Japan, and one in Hong Kong.

OKMETIC'S CORPORATE GOVERNANCE

Okmetic Oyj's annual general meeting, which was held on 12 April 2012, adopted the annual accounts and the consolidated annual accounts for 2011 and discharged the company's management from liability. It was decided that a dividend of 0.28 euro per share would be distributed for 2011. The dividend was paid on Tuesday 24 April 2012. The annual general meeting decided also, in accordance with the proposal of the board of directors, to authorise the board of directors to decide upon its discretion on the payment of an additional dividend, should the company's financial situation permit this. The additional dividend, including all possible separate decisions on dividend payment, may amount up to a maximum of 0.40 euro per share and 15,000,000 euro in total. Moreover, the general meeting approved the proposal of the board of directors to authorise the board of directors to decide on the repurchase and/or the acceptance as pledge of the company's own shares as well as on the issuance of shares, the transfer of the company's own shares, and the issuance of special rights entitling to shares.

It was decided that there would be five members on the company's board of directors. Mr. Henri Österlund, Mr. Tapani Järvinen, Mr. Hannu Martola, and Ms. Mervi Paulasto-Kröckel were re-elected as members of the board of directors until the end of the next annual general meeting, and Mr. Mikko Puolakka was elected as a new member. The board of directors elected Henri Österlund as its chairman and Tapani Järvinen as its vice chairman in its organisation meeting held immediately after the annual general meeting.

Authorised Public Accountant PricewaterhouseCoopers Oy was elected as auditor, with APA Mikko Nieminen having the principal responsibility.

Authorisations given to the board of directors and other decisions of the annual general meeting have been notified in a stock exchange release published on 12 April 2012.

BUSINESS RISKS IN THE NEAR FUTURE

There have been no essential changes in the company's near future business risks and uncertainties. Okmetic's business operations are exposed to risks which may arise from the company's operations or changes in the business environment.

Okmetic's silicon wafer sales are targeted at the sensor and semiconductor producers in the electronics industry. The demand for semiconductor wafers is sensitive to economic fluctuations and changes in the market situation can be sudden and dramatic. The demand for sensor wafers is more stable. The proliferation of sensors in consumer electronics applications may, however, increase the susceptibility of this market too to economic fluctuations. Technology sales comprise mainly crystal sales, which is predominantly affected by the economic situation of the solar cell industry.

Okmetic's share of the global silicon wafer market is around one percent and the market prices have a notable effect on the price development of Okmetic's products. The company only has considerable pricing power with its own special products. The pricing of other wafers is mainly based on global market price.

Okmetic operates globally, and therefore the company's business operations are affected by risks due to currency fluctuations, consisting of the cash flows of purchases and sales. A significant part of sales are conducted in US dollars. The Japanese yen is another notable trading currency. Despite hedging, the company remains exposed to exchange rate fluctuations.

Substantial volumes of electricity are used in Okmetic's production. Despite hedging, the company is exposed to fluctuations in the price of electricity.

The company risks and uncertainty factors are dealt more profoundly in the company's annual report of 2011.

SHARES AND SHAREHOLDERS

On 31 March 2012, Okmetic Oyj's paid-up share capital, as entered in the Finnish Trade Register, was 11,821,250.00 euro. The number of shares was 17,287,500. The shares have no nominal value attached. Each share entitles its holder to one vote at general meetings. The company has one class of shares. The company's shares are included in the Finnish book-entry securities system.

 

SHARE PRICE DEVELOPMENT AND TRADING

A total of 1.1 (3.6) million shares were traded between 1 January and 31 March 2012, representing 6.6 (20.8) percent of the weighted average of share total of 17.3 (17.3) million during the period. The lowest quotation during the period was 4.98 (5.30) euro, and the highest 6.01 (6.65) euro, with the average being 5.63 (5.90) euro. The closing quotation for the period was 5.82 (6.55) euro. At the end of the period, the market capitalisation amounted to 100.6 (113.2) million euro.

OWN SHARES AND DIRECTED SHARE ISSUES

On 8 February 2012, Okmetic Oyj's board of directors announced of its decision to transfer a total of 56,033 own shares held by the company as a part of the company's share-based incentive scheme for the executive management group, of which the company has given a stock exchange release on 11 February 2010. All the shares were issued to the members of the executive management group in deviation from the shareholders' pre-emptive rights (directed share issue).

The rewards of the share reward programme were paid on one hand in Okmetic shares and on the other hand in a monetary amount covering taxes. The directed share issue without payment was executed in full as there was no consideration related to the issue.

At the end of the reporting period Okmetic held 241,543 own shares, which is approximately 1.4 percent of Okmetic's all shares and votes. 

OTHER EVENTS IN THE INTERIM PERIOD

The company Kiinteistö Oy Piitalot which was part of Okmetic group has merged with Okmetic Oyj on 1 January 2012. Its assets and liabilities were transferred to Okmetic Oyj.

 

The Helsinki Court of Appeal gave a verdict in January in which it decided not to change the acquittal for President Kai Seikku rendered by the Helsinki District Court on 20 December 2010 and dismissed the prosecutor's claims on negligent abuse of insider information. The Helsinki Court of Appeal's verdict has entered into legal force as the prosecutor did not request for leave to appeal from the next instance. The charge was related to Seikku's actions while he was still working for his previous employer HKScan Oyj.

CONDENSED FINANCIAL STATEMENTS AND TABLES 1 JANUARY - 31 MARCH 2012 (unaudited)

ACCOUNTING POLICIES

These interim financial statements have been prepared in accordance with IAS 34, Interim Financial Reporting.

In preparing these interim financial statements, Okmetic has followed the same accounting policies as in the financial statements for 2011 except for the effect of changes required by the adoption of the following new or revised standards and interpretations as of 1 January 2012:

-IFRS 7 (amendment), Financial instruments: Disclosures - Derecognition.
-IAS 12 (amendment), Income Taxes - Deferred Tax.

The adoption of the aforementioned standards and interpretations has not had an effect on the figures presented from the reporting period.

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

1,000 euro 1 Jan-
31 Mar,
2012
1 Jan-
31 Mar,
2011
1 Jan-
31 Dec,
2011
Net sales 18,902 22,055 83,186
Cost of sales -14,851 -15,939 -61,876
Gross profit 4,051 6,116 21,310
Other income
and expenses

-2,515

-3,288

-9,493
Operating
profit

1,535

2,828

11,817
Financial
income and
expenses


-307


-532


-479
Profit before
tax

1,229

2,296

11,339
Income tax -517 428 -1,104
Profit for
the period

712

2,724

10,235
Other
comprehensive
income:
Cash flow
hedges

127

-

-177
Translation
differences

-106

-203

808
Other
comprehensive
income for the
period, net of
tax




21




-203




631
Total
comprehensive
income for
the period



733



2,521



10,866
Profit for
the period
attributable
to:
Equity holders
of the parent
company


712


2,724


10,235
Total
comprehensive
income
attributable
to:
Equity holders
of the parent
company


733


2,521


10,866
Basic earnings
per share,
euro


0.04


0.16


0.61
Diluted
earnings per
share, euro


0.04


0.16


0.59

CONDENSED CONSOLIDATED BALANCE SHEET

1,000 euro 31 Mar,
 2012
31 Mar,
 2011
31 Dec,
2011
Assets
Non-current assets
Intangible assets 83 - -
Property, plant and
equipment

35,847

32,065

34,887
Other receivables 3,696 4,251 3,255
Total non-current
assets

39,626

36,316

38,142
Current assets
Inventories 14,963 10,319 13,114
Receivables 16,933 17,461 15,374
Financial assets at
fair value through
profit or loss


-


3,013


-
Cash and cash
equivalents

7,154

10,366

11,257
Total current assets 39,049 41,158 39,745
Total assets 78,675 77,475 77,887
Equity and liabilities
Equity
Equity attributable
to equity holders of
the parent company
Share capital 11,821 11,821 11,821
Other equity 49,914 49,199 49,151
Total equity 61,735 61,021 60,973
Liabilities
Non-current
liabilities

3,272

1,526

2,968
Current liabilities 13,669 14,927 13,946
Total liabilities 16,940 16,454 16,914
Total equity and
liabilities

78,675

77,475

77,887

CONDENSED CONSOLIDATED CASH FLOW STATEMENT

1,000 euro 1 Jan-
31 Mar,
 2012
1 Jan-
31 Mar,
2011
1 Jan-
31 Dec,
2011
Cash flows from operating
activities:
Profit before tax 1,229 2,296 11,339
Adjustments 2,192 2,735 7,575
Change in working capital -3,878 -5,950 -6,782
Financial items 11 -419 -401
Tax paid -520 - -39
Net cash from
operating activities

-966

-1,337

11,691
Cash flows from investing
activities:
Purchases of property,
plant and equipment

-2,624

-3,908

-11,319
Investments in fixed
income funds

-

2,003

5,016
Net cash used in investing
activities

-2,624

-1,905

-6,302
Cash flows from financing
activities:
Repayments of long-term
borrowings

-

-

-
Payments of finance
lease liabilities

-

-

-
Share issue - - -
Repurchase of own shares - - -1,147
Dividends paid -201 - -7,331
Net cash used in financing
activities

-201

-

-8,478
Increase (+) /
decrease (-)in cash
and cash equivalents


-3,791


-3,243


-3,089
Exchange rate changes -313 -434 304
Cash and cash
equivalents at
the beginning
of the period



11,257



14,043



14,043
Cash and cash
equivalents at
the end of the
period



7,154



10,366



11,257

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

Equity attributable to equity holders of parent company
1,000 euro Share
capital
Share
pre-
mium
Reserve
for in-
vested
unre-
stricted
equity
Other
re-
serves
1)
Retained
earnings
Total
Balance at
31 dec, 2011

11,821

20,045

1,200

1,670

26,238

60,973
Profit for
the period

712

712
Other com-
prehensive
income, net
of tax:
Cash flow
hedges

127

127
Translation
differences

-106

-106
Total com-
prehensive
income for
the period



21



712



733
Share-based
payments

29

29
Balance at
31 Mar, 2012

11,821

20,045

1,200

1,691

26,977

61,735
Balance at
31 Dec, 2010

11,821

20,045

1,200

1,039

24,137

58,242
Profit for
the period

2,724

2,724
Other com-
prehensive
income, net
of tax:
Translation
differences

-203

-203
Total com-
prehensive
income for
the period



-203



 2,724



2,521
Share-based
payments

258

258
Balance at
31 Mar, 2011

11,821

20,045

1,200

836

27,118

61,021

1)"Other reserves" contains hedge reserve and translation differences.

CHANGES IN PROPERTY, PLANT AND EQUIPMENT

1,000 euro                 
                                    Â
1 Jan-
31 Mar,
2012
1 Jan-
31 Mar,
2011
1 Jan-
31 Dec,
2011
Carrying amount
at the beginning
of the period


34,887


29,069


29,069
Additions 2,592 4,837 11,992
Disposals - - -
Depreciation 1,512 -1,597 -6,252
Exchange differences -120 -245 78
Carrying amount
at the end of
the period


35,847


32,065


34,887

COMMITMENTS AND CONTINGENCIES

1,000 euro 31 Mar,
2012
31 Mar,
2011
31 Dec,
2011
Loans, secured with
collaterals

1,000

1,000

1,000
Collaterals 8,073 8,073 8,073
Off-balance sheet
lease commitments

435

206

426
Capital commitments 6,199 4,226 5,424
Nominal values of
derivative contracts
Currency options,
call

-

9,699

652
Currency options,
put

-

5,146

652
Currency forward
agreements

154

-

154
Electricity
derivatives

2,958

1,703

2,173
Fair values of
derivative contracts
Currency options,
call

-

226

0
Currency options,
put

-

-9

-81
Currency forward
agreements

5

-

1
Electricity
derivatives

-309

-210

-330

The contract price of the derivatives has been used as the nominal value of the underlying asset.

KEY FIGURES SHOWING FINANCIAL PERFORMANCE

1,000 euro 1 Jan-
31 Mar,
2012
1 Jan-
31 Mar,
2011
1 Jan-
31 Dec,
2011
Net sales 18,902 22,055 83,186
Change in net sales
compared to the previous
year's period, %


-14.3


33.5


2.8
Export and foreign
operations share
of net sales, %


95.1


94.6


94.4
Operating profit before
depreciation (EBITDA)

3,052

4,425

18,069
    % of net sales 16.1 20.1 21.7
Operating profit 1,535 2,828 11,817
    % of net sales 8.1 12.8 14.2
Profit before tax 1,229 2,296 11,339
    % of net sales 6.5 10.4 13.6
Return on equity, % 4.6 18.3 17.2
Return on investment, % 7.9 15.1 18.7
Non-interest-bearing
liabilities

15,857

15,454

15,914
Net interest-bearing
liabilities

-6,071

-12,379

-10,257
Net gearing ratio, % -9.8 -20.3 -16.8
Equity ratio, % 79.2 78.9 78.9
Capital expenditure 2,592 4,837 11,992
    % of net sales 13.7 21.9 14.4
Depreciation 1,517 1,597 6,252
Research and development
expenditure

535

595

2,382
    % of net sales 2.8 2.7 2.9
Average number of
personnel during
the period


351


347


363
Personnel at the
end of the period

352

351

350

KEY FIGURES PER SHARE

Euro 31 Mar,
2012
31 Mar,
2011
31 Dec,
2011
Basic earnings
per share

0.04

0.16

0.61
Diluted earnings
per share

0.04

0.16

0.59
Equity per share 3.69 3.63 3.68
Dividend per share - - 0.28
Dividends/earnings, % - - 45.8
Effective dividend
yield, %

-

-

5.7
Price/earnings(P/E) - - 8.0
Share performance (1.1.-)
Average trading price 5.63 5.90 5.48
Lowest trading price 4.98 5.30 3.50
Highest trading price 6.01 6.65 6.65
Trading price at the
end of the period

5.82

6.55

4.92
Market capitalisation
at the end of the
period, 1,000 euro


100,613


113,233


85,055
Trading volume (1 Jan-)
Trading volume,
transactions, 1,000 pcs

1,141

3,601

10,907
In relation to weighted
average number of
shares, %


6.6


20.8


63.1
Trading volume,
1,000 euro

6,422

21,242

59,650
The weighted average
number of shares during
the period under review
adjusted by the share
issue, 1,000 pcs




17,288




17,288




17,288
The number of shares at
the end of the period
adjusted by the share
issue, 1,000 pcs



17,288



17,288



17,288

When calculating earnings per share (EPS) and equity, Okmetic's own shares in its possession and Okmetic's shares owned by Okmetic Management Oy are deducted from the amount of shares.

QUARTERLY KEY FIGURES

1,000 euro 10-12/
2012
7-9/
2012
4-6/
2012
1-3/
2012
Net sales 18,902
  Compared to previous
  quarter, %

4.2
  Compared to corresponding
  period last year, %

-14.3
Operating profit 1,535
  % of net sales 8.1
Profit before tax 1,229
  % of net sales 6.5
Net cash flow generated
from:
Operating activities


-966
Investing activities -2,624
Financing activities -201
Increase/decrease in cash
and cash equivalents

-3,791
Personnel at the end
of the period

352

1,000 euro 10-12/
2011
7-9/
2011
4-6/
2011
1-3/
2011
Net sales 18,134 21,250 21,747 22,055
  Compared to previous
  quarter, %

-14.7

-2.3

-1.4

-4.4
  Compared to corresponding
  period last year, %

-21.4

-1.7

10.5

33.5
Operating profit 2,338 4,045 2,606 2,828
  % of net sales 12.9 19.0 12.0 12.8
Profit before tax 2,439 4,117 2,487 2,296
  % of net sales 13.4 19.4 11.4 10.4
Net cash flow generated
from:
Operating activities


5,431


2,094


5,503


-1,337
Investing activities -4,332 -1,100 1,035 -1,905
Financing activities -2,771 -664 -5,043 -
Increase/decrease in cash
and cash equivalents

-1,672

330

1,495

-3,243
Personnel at the end
of the period

350

350

389

351

MAJOR SHAREHOLDERS ON 31 MARCH 2012

  Shares,
pcs
Share,
%
Ilmarinen Mutual Pension
Insurance Company

1,666,601

9.6
Mandatum Life Insurance
Company Limited

810,500

4.7
The State Pension Fund 600,000 3.5
Varma Mutual Pension
Insurance Company

477,175

2.8
Veritas Pension
Insurance Company Ltd.

465,000

2.7
Okmetic Management oy 400,000 2.3
Etra-Invest Oy Ab 400,000 2.3
Nordea Nordic Small
Cap Fund

370,660

2.1
Okmetic Oyj 241,543 1.4
Sijoitusrahasto Taaleritehdas
Arvo Markka Osake

225,100

1.3
Kaleva Mutual Insurance
Company

212,700

1.2
Aktia Secura Fund 201,182 1.2
Oy Ingman Finance Ab 200,051 1.2
Sijoitusrahasto Aktia Capital 140,387 0.8
EQ Pikkujättiläiset /
EQ Rahastoyhtiö

140,000

0.8
Kiilholma Antti Tapio 92,248 0.5
Stenhäll Turo 75,000 0.4
Virtanen Yhtiöt Oy 70,000 0.4
Sr Eq Technology 60,000 0.4
Sr Arvo Finland Value 56,611 0.3
Foreign investors and
nominee accounts held by
custodian banks


3,141,131


18.2
Others 7,241,611 41.9
Total 17,287,500 100.0

DEFINITIONS OF KEY FINANCIAL FIGURES

Operating profit before depreciation (EBITDA) = Operating profit + depreciation
Return on equity (ROE), % = Profit/loss for the period x 100/
Equity(Average for the period)
Return on investment (ROI), % = (Profit/loss before tax + interest and other financial expenses) x 100/
Balance sheet total - non-interest bearing liabilities(average for the period)
Equity ratio, % = Equity x 100/
Balance sheet total - advances received
Net interest-bearing liabilities = Interest-bearing liabilities - cash and cash equivalents
Net gearing ratio, % = (Interest-bearing liabilities - cash and cash equivalents) x 100/
Equity
Earnings per share = Profit/loss for the period attributable to  equity holders of the parent company/
Adjusted weighted average number of shares in issue during the period
Equity per share = Equity attributable to equity holders of the parent company/
Adjusted number of shares at the end of the period
Dividend per share = Dividend for the period/
Adjusted number of shares at the end of the period
Effective dividend yield, % = Dividend per share x 100/
Trading price at the end of the period
Price/earnings ratio (P/E) = Last adjusted trading price at the end of the period/
Earnings per share
Average trading price = Total traded amount in euro/
Adjusted number of shares traded during the period
Market capitalisation at the end of the period = Number of shares at the end of the period x trading price at the end of the period
Trading volume = Number of shares traded during the period/
Weighted average number of shares during the period

All figures of the financial tables are rounded, and consequently the sum of individual figures can deviate from the presented sum figure.

The future estimates and forecasts in this interim report are based on company management's current knowledge. Actual events and results may differ from the estimates presented here.

PRESS CONFERENCE

A press conference for the media and analysts will be held on Friday, 27 April 2012 at 1.00 p.m. at Helsinki World Trade Center, Aleksanterinkatu 17, second floor, Helsinki. In the conference, Okmetic's President Kai Seikku will present the group's development in January-March 2012 and prospects for 2012.

We ask participants to kindly give advance notice of their attendance by email to communications@okmetic.com or by telephone to +358 9 5028 0406/Marika Mäntymaa.

OKMETIC OYJ

Board of directors

For further information, please contact:

President Kai Seikku, Okmetic Oyj,
tel. +358 400 200 288, email: kai.seikku@okmetic.com

Senior Vice President, Finance, IT, and Communications
Juha Jaatinen, Okmetic Oyj, tel. +358 9 5028 0286,
email: juha.jaatinen@okmetic.com

Distribution:
NASDAQ OMX Helsinki
Principal media
www.okmetic.com (http://www.okmetic.com/)

OKMETIC IN BRIEF

Take it higher

Okmetic is a technology company which supplies tailor-made silicon wafers for sensor and semiconductor industries and sells its technological expertise to the solar cell industry. Okmetic provides its customers with solutions that boost their competitiveness and profitability.

Okmetic's silicon wafers are part of a further processing chain that produces end products that improve human interaction and quality of life. Okmetic's products are based on high-tech expertise that generates added value for customers, innovative product development and an extremely efficient production process. 

Okmetic has a global customer base and sales network, production plants in Finland and the US and contract manufacturers in Japan and China. Okmetic's shares are listed on NASDAQ OMX Helsinki under the code OKM1V. For more information on the company, please visit our website at www.okmetic.com.

OKME1112 (http://hugin.info/132025/R/1606466/509274.pdf)



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Okmetic Oyj via Thomson Reuters ONE

HUG#1606466
© 2012 GlobeNewswire (Europe)
Software vor dem Comeback – diese 5 Aktien könnten durchstarten!
Während Halbleiter- und KI-Infrastrukturwerte von einem Hoch zum nächsten jagen, wurden viele Software-Aktien in den vergangenen Monaten regelrecht aus den Depots gedrängt. Die Angst vor Disruption hat Investoren zu einem radikalen Strategiewechsel veranlasst – mit der Folge, dass zahlreiche Qualitätsunternehmen heute auf Mehrjahrestiefs notieren.

Doch genau hier entsteht eine seltene Chance. Denn während die Bewertungen im Halbleitersektor inzwischen auf ambitionierten Niveaus liegen, ist der Bewertungsabschlag bei Software-Titeln so hoch wie seit Jahren nicht mehr. Gleichzeitig liefern viele Unternehmen weiterhin starke Wachstumszahlen und integrieren KI erfolgreich in ihre Geschäftsmodelle. Die Diskrepanz zwischen Kursentwicklung und operativer Stärke könnte sich schon bald auflösen.

Für Anleger bedeutet das: antizyklisch denken und gezielt zugreifen, bevor der Markt dreht. Denn erste technische Signale deuten darauf hin, dass sich die Trendwende bereits anbahnt.

In unserem aktuellen Spezialreport stellen wir fünf Software-Aktien vor, die besonders aussichtsreich positioniert sind – mit starker Marktstellung, attraktiver Bewertung und hohem Aufholpotenzial.

Jetzt den kostenlosen Report sichern – bevor der Software-Rebound Fahrt aufnimmt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.